Nanjing Leads Biolabs' (HKG:9887) new drug application for LBL-024 was accepted by China's National Medical Products Administration.
The acceptance is for the drug as monotherapy for the treatment of previously treated advanced extrapulmonary neuroendocrine carcinoma, according to a Friday Hong Kong bourse filing.